| Median age at diagnosis [yr](range) |
8(1-45) |
| Disease, n(%) |
|
| SAA or VSAA |
72(93) |
| SAA&PNH |
5(7) |
| IST prior to referral for HSCT, n(%) |
|
| ATG included |
15(19) |
| ATG excluded |
62(81) |
| Transfusion RBC before HSCT, U(%) |
|
| ≥25U |
29(38) |
| <25U |
48(62) |
| Median age at transplant [yr](range) |
11(1-46) |
| ≤15yr, n(%) |
52(67) |
| >15yr, n(%) |
25(33) |
| Median disease duration before HSCT[m](range) |
7(2-182) |
| Sex(female/male) |
38/39 |
| Source of stem cells, n(%) |
|
| BM+PB |
77(100) |
| Regimen, n(%) |
|
| A(Flu+Cy+ATG+Bu) |
42(54) |
| B(Flu+Cy+ATG) |
35(46) |
| Median MNCs, ×108/kg (range) |
10.10(6.30-33.63) |
| Median CD34+, ×106/kg (range) |
4.77(1.01-17.72) |
| Engraftment, n(%) |
|
| Primary engraftment |
74(96) |
| Secondary engraftment |
3(4) |
| Median time of ANC ≥0.5 × 109/L [d](range) |
12(8-21) |
| Median time to PLT ≥20 × 109/L [d](range) |
14(9-30) |
| aGVHD, n(%) |
|
| Grades II-IV |
20(26) |
| Grade III-IV |
8(10) |
| cGVHD, n(%) |
|
| Limited |
14(18) |
| Extensive |
5(7) |
| Median follow-up time [m](range) |
20(1-66) |
